The latest chapter in an ongoing saga over European supplies of AstraZeneca’s (LSE: AZN) coronavirus vaccine looks likely to involve legal action.
The European Commission is reportedly asking the 27 EU member states to back litigation against the British firm, which it says is in breach of contractual obligations to supply the product, Vaxzevria.
AstraZeneca has said it inked a so-called “best efforts” contract with Europe, and that supply chain disruptions prevented it from supplying the estimated amount.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze